Mark Lowey

Vancouver biotech firm AbCellera wins SIF research funding to fast-track antibody therapies against COVID-19

Mark Lowey
March 23, 2020

Vancouver-based biotech firm AbCellera, using its technology spun off research at University of British Columbia, is fast-tracking testing and clinical trials of therapeutic antibodies against COVID-19.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics
Organizations: AbCellera, Bill and Melinda Gates Foundation, DCVC Bio, Defense Advanced Research Projects Agency, Denali, Eli Lilly and Company, Fast Company, Gilead, Government of Canada, Novartis, U.S. Department of Defense, U.S. National Institutes of Health, and University of British Columbia
People: Carl Hansen, Daniel Akovronsky, and Prime Minister Justin Trudeau
Topics: biopharmaceutical industry, biotechnology, coronavirus pandemic, COVID-19, early stage clinical trials, Government Funding, infectious diseases, microfluidics technology, new drugs development, Strategic Innovation Fund COVID-19 stream, therapeutic antibodies, University Research, and Venture Capital

Other News

Quebec’s latest budget aims to boost competitiveness and innovation through enhanced tax incentives

New report shows that research gender gap is closing, but not for women inventors

The Short Report, March 18, 2020: Canadian researchers take first steps to a COVID-19 vaccine, University of Alberta announces drastic cuts, and more

The Short Report, March 11, 2020: Anonymizing research applications mitigates gender bias; Superclusters spend a fraction of their budget; Athena Pathways aims to train 500 women in AI






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.